Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-1

Angiopoietin-1

Brief Information

Name:Angiopoietin-1
Target Synonym:KIAA0003,ANGPT1,Angiopoietin 1,ANG-1,AGP1,AGPT,ANG1,Angiopoietin-1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Synonym Name

ANGPT1,AGP1,AGPT,ANG1,Angiopoietin-1

Background

Binds and activates TEK/TIE2 receptor by inducing its dimerization and tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Required for normal angiogenesis and heart development during embryogenesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. Mediates blood vessel maturation/stability. Implicated in endothelial developmental processes later and distinct from that of VEGF. Appears to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
DBPR-114 DBPR-114 Phase 1 Clinical National Health Research Institutes Neoplasms Details
Trebananib AMG-386; 20060439 Amgen Inc, Takeda Pharmaceutical Co Ltd Details
Recombinant NAPc2 AB-201 Phase 3 Clinical Dendreon Uk Ltd Coronavirus Disease 2019 (COVID-19) Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message